



Salmonella enterica Serovar Typhimurium Exploits Cycling through Epithelial Cells To Colonize Human and Murine Enteroids

Petra Geiser,^a
 Maria Letizia Di Martino,^a
 Pilar Samperio Ventayol,^a
 Jens Eriksson,^a
 Eduardo Sima,^b
 Anas Kh. Al-Saffar,^{c*}
 David Ahl,^d
 Mia Phillipson,^d
 Dominic-Luc Webb,^c
 Magnus Sundbom,^b
 Per M. Hellström,^c
 Mikael E. Sellin^a

^aScience for Life Laboratory, Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden

^bDepartment of Surgical Sciences, Uppsala University, Uppsala, Sweden

^cDepartment of Medical Sciences, Gastroenterology and Hepatology Unit, Uppsala University, Uppsala, Sweden

^dDepartment of Medical Cell Biology, Uppsala University, Uppsala, Sweden

ABSTRACT Enterobacterial pathogens infect the gut by a multistep process, resulting in colonization of both the lumen and the mucosal epithelium. Due to experimental constraints, it remains challenging to address how luminal and epithelium-lodged pathogen populations cross-feed each other *in vivo*. Enteroids are cultured three-dimensional miniature intestinal organs with a single layer of primary intestinal epithelial cells (IECs) surrounding a central lumen. They offer new opportunities to study enterobacterial infection under near-physiological conditions, at a temporal and spatial resolution not attainable in animal models, but remain poorly explored in this context. We employed microinjection, time-lapse microscopy, bacterial genetics, and barcoded consortium infections to describe the complete infection cycle of *Salmonella enterica* serovar Typhimurium in both human and murine enteroids. Flagellar motility and type III secretion system 1 (TTSS-1) promoted *Salmonella* Typhimurium targeting of the intraepithelial compartment and breaching of the epithelial barrier. Strikingly, however, TTSS-1 also potently boosted colonization of the enteroid lumen. By tracing the infection over time, we identified a cycle(s) of TTSS-1-driven IEC invasion, intraepithelial replication, and reemergence through infected IEC expulsion as a key mechanism for *Salmonella* Typhimurium luminal colonization. These findings suggest a positive feed-forward loop, through which IEC invasion by planktonic bacteria fuels further luminal population expansion, thereby ensuring efficient colonization of both the intraepithelial and luminal niches.

IMPORTANCE Pathogenic gut bacteria are common causes of intestinal disease. Enteroids—cultured three-dimensional replicas of the mammalian gut—offer an emerging model system to study disease mechanisms under conditions that recapitulate key features of the intestinal tract. In this study, we describe the full life cycle of the prototype gut pathogen *Salmonella enterica* serovar Typhimurium within human and mouse enteroids. We map the consecutive steps and define the bacterial virulence factors that drive colonization of luminal and epithelial compartments, as well as breaching of the epithelial barrier. Strikingly, our work reveals how bacterial colonization of the epithelium potently fuels expansion also in the luminal compartment, through a mechanism involving the death and expulsion of bacterium-infected epithelial cells. These findings have repercussions for our understanding of the *Salmonella* infection cycle. Moreover, our work provides a comprehensive foundation for the use of microinjected enteroids to model gut bacterial diseases.

KEYWORDS bioimaging, *Enterobacteriaceae*, enteroid, gastrointestinal infection, *Salmonella*

Citation Geiser P, Di Martino ML, Samperio Ventayol P, Eriksson J, Sima E, Al-Saffar AK, Ahl D, Phillipson M, Webb D-L, Sundbom M, Hellström PM, Sellin ME. 2021. *Salmonella enterica* serovar Typhimurium exploits cycling through epithelial cells to colonize human and murine enteroids. *mBio* 12:e02684-20. <https://doi.org/10.1128/mBio.02684-20>.

Editor Vanessa Sperandio, University of Texas Southwestern Medical Center Dallas

Copyright © 2021 Geiser et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Mikael E. Sellin, mikael.sellin@imbim.uu.se.

* Present address: Anas Kh. Al-Saffar, Department of Surgery and Obstetrics, College of Veterinary Medicine, Baghdad University, Baghdad, Iraq.

Received 27 September 2020

Accepted 17 November 2020

Published 12 January 2021

Salmonella enterica serovar Typhimurium is a common foodborne pathogen infecting the intestine of humans and other warm-blooded animals to cause acute enterocolitis. As a prototypic enteropathogen, *Salmonella* Typhimurium has been used to model the mechanisms underlying gut lumen colonization and the interplay with intestinal epithelial cells (IECs) and other mucosal cell types (1). Following ingestion of the pathogen, planktonic *Salmonella* Typhimurium expansion in the gut lumen and invasion of IECs both occur during the early phase of the infection (1). Flagellar motility and chemotaxis allow luminal *Salmonella* Typhimurium to penetrate the protective mucus layer and reach the epithelium, where the pathogen engages in near-surface swimming to scan for suitable target sites (2–6). Binding to the apical surface of IECs depends on bacterial adhesins and the syringe-like type III secretion system 1 (TTSS-1), encoded by *Salmonella* pathogenicity island 1 (SPI-1) (7–10). TTSS-1 subsequently induces bacterial uptake through transfer of a cocktail of effector proteins into the host cell (11–15). Hence, both flagella and TTSS-1 are critical virulence factors during gut colonization and drive IEC invasion both in tissue culture models and *in vivo* (1, 16).

Following internalization into IECs, *Salmonella* Typhimurium downregulates TTSS-1 and flagella and expresses a second TTSS (TTSS-2) encoded by SPI-2 to control intracellular trafficking and establish an intracellular niche (15, 17–19). The pathogen population expands within a vacuolar compartment referred to as the *Salmonella*-containing vacuole (SCV) (18, 20–23). Cytosolic hyperreplication, resulting from vacuolar escape, has also been reported in cultured epithelial cells (20, 21, 24). In addition, some IEC-invading *Salmonella* Typhimurium organisms can breach the epithelial barrier, thus initiating systemic bacterial spread (15, 17, 18, 25). However, the life span of the intraepithelial *Salmonella* Typhimurium population is limited by IEC-intrinsic, inflammasome-dependent detection and expulsion of infected IECs from the epithelium (17, 20, 22, 26, 27). Previous findings (17, 20) have hinted that bacterium-containing expelled IECs might contribute to *Salmonella* Typhimurium reseeding of the lumen, but the extent to which IEC invasion and luminal colonization are causally linked remains unclear.

Traditionally, *Salmonella* Typhimurium gut infection has been studied in *in vivo* models such as streptomycin-pretreated mice (28) or ligated bovine and rabbit ileal loops (29, 30) on one hand and in transformed/immortalized epithelial cell line cultures on the other (9, 12, 31). While they are physiologically relevant, the temporal resolution and control of experimental parameters remain poor in the *in vivo* models. In contrast, cell line infections allow stringent experimental control but lack three-dimensional (3D) tissue compartmentalization and primary cell behavior, and thus, they insufficiently model key aspects of the infection. A recent study revealed that the mechanistic basis for *Salmonella* Typhimurium invasion of IECs varies considerably between cell line infection models and the intact murine gut (11). This highlights the need to bridge the gap between physiological relevance and experimental simplicity when gut infectious diseases are being studied.

Gastrointestinal organotypic cultures containing primary epithelial cells provide a promising opportunity in this context. Such cultures can be established from pluripotent stem cells (referred to as PS-derived epithelial organoids) (32–35) or from adult stem cells residing in gastrointestinal crypts (resulting in exclusively epithelial structures termed gastroids, enteroids, or colonoids, depending on the segment of origin) (36–41). When grown in their 3D arrangement, these organotypic cultures feature a single-layered epithelium, encapsulating a central lumen that can be accessed by microinjection. Enterobacterial infections have recently been modeled in human PS-derived 3D organoids (42–45), murine 3D enteroids (46–48), and enteroid-derived 2D epithelial monolayers (49–54) or polarity-inverted 3D structures (55) that lack a luminal compartment. Experiments in human 3D gastroids have provided mechanistic insights into *Helicobacter pylori* infection (38, 56, 57). Microinjected human 3D enteroids, though recently used to investigate parasite infection (58, 59), have however remained virtually unexplored as a model for enterobacterial infection.

In this study, we validated microinjection of human and murine enteroids with

fluorescent *Salmonella* Typhimurium as a 3D infection model with high temporal and spatial resolution. This permitted the tracing of both luminal and IEC-lodged *Salmonella* Typhimurium populations across the infection cycle by time-lapse microscopy. Using bacterial mutants, we identified flagellar motility as the main contributor to breaching of the epithelial barrier. In addition, our analyses established that cycles of TTSS-1-dependent IEC invasion, intraepithelial replication, and expulsion of infected IECs potentially complement planktonic *Salmonella* Typhimurium growth for efficient colonization of the enteroid lumen.

RESULTS

Enteroid microinjection recapitulates key steps of the early *Salmonella* Typhimurium gut infection cycle. Early *Salmonella* Typhimurium infection involves luminal growth and IEC invasion. The steps of IEC invasion comprise (i) *Salmonella* Typhimurium flagellar motility, (ii) binding and TTSS-1-dependent invasion, (iii) intraepithelial replication within an SCV and/or in the cytosol, (iv) inflammasome-driven expulsion of infected IECs, and in some cases (v) bacterial breaching of the epithelial barrier. To validate enteroid microinjection as a model for these infection cycle events, human jejunum enteroids were established, injected with wild type (WT) *Salmonella* Typhimurium (SL1344) constitutively expressing mCherry (*rpsM*-mCherry) (60), and imaged by time-lapse microscopy (Fig. 1A; time-lapse movies related to the figures are available at <https://doi.org/10.17044/scilifelab.12998570>).

Microinjected *Salmonella* Typhimurium maintained flagellar motility, reached the epithelial surface within seconds after injection (Fig. 1A), and engaged in near-surface swimming (Fig. 1B). Tracking of individual bacteria revealed approximately similar levels of motile bacteria and average swimming speeds in the enteroid lumen and in the inoculum (Fig. 1B and C). Following injection, we observed a gradual increase in the numbers of fluorescent bacteria in the enteroid lumen, highlighting luminal replication over several hours post-injection (p.i.) (Fig. 1D). Luminal expansion with broadly similar kinetics was observed in spheroid human enteroids (Fig. 1D) and in morphologically more elaborate murine (C57BL/6 jejunum origin; two independently established enteroid lines) and human enteroids with clearly distinguishable crypt and villus domains (see Fig. S1 in the supplemental material). However, since microinjection of multilobulated enteroids was technically more challenging and quantification was more accurate in sphere-shaped enteroids with a clearly visible lumen, we used the latter for further analyses.

Salmonella Typhimurium invasion foci within IECs were detected shortly after injection and continued to accumulate during the following hours (Fig. 1E, left). To investigate the timing of SCV establishment inside IECs, we injected enteroids with *Salmonella* Typhimurium expressing SPI-2-inducible green fluorescent protein (GFP) upon host cell invasion (*pssaG*-GFP) (15). The appearance of GFP-positive intraepithelial foci at ~3 to 4 h p.i. confirmed successful SCV establishment in some IECs (Fig. 1E, right; also, see Fig. S2A and B), and the expansion of these foci demonstrated intraepithelial replication (Fig. 1F). Applying a reporter induced upon access to the cytosolic metabolite glucose-6-phosphate (*puhpT*-GFP) (18), we assessed the existence of *Salmonella* Typhimurium in the IEC cytosol. In agreement with recent observations in primary IECs by others (53), *puhpT*-GFP-positive foci were few and barely detectable in the enteroid model (Fig. S2C). Furthermore, restriction of intraepithelial *Salmonella* Typhimurium included the frequent expulsion of bacterium-containing IECs into the enteroid lumen, detectable as early as ~60 to 90 min p.i. (Fig. 1G; Fig. S2B and D). While the *Salmonella* Typhimurium population was contained within the epithelial lining during the first hours (Fig. 1D), breaching of the epithelial barrier was observed at later time points (Fig. 1H). Bacterial escape as a rule originated from an IEC invasion focus (Fig. 1H) and could be seen as a simple proxy for systemic *Salmonella* Typhimurium spread in the enteroid model.

Microbe-host interactions in organotypic models can exhibit considerable donor-to-donor variation (61–63). To exclude donor-specific effects, the *Salmonella* Typhimurium infectious cycle was replicated in a second independently established human enteroid




FIG 1 Recapitulation of the *Salmonella* Typhimurium early infection cycle in the human enteroid microinjection model. Human enteroids were injected with *Salmonella* Typhimurium (S.Tm) WT harboring the constitutive *rpsM*-mCherry or the SPI-2-inducible *pssaG*-GFP reporter and imaged by wide-field differential interference contrast (DIC) and fluorescence time-lapse microscopy. (A) Microinjection procedure. Arrowheads indicate individual bacteria that have reached the epithelial surface. (B) Tracking of individual bacteria within the enteroid lumen. *Salmonella* Typhimurium organisms within the enteroid lumen, as well as a 1:700 to 1:1,000 dilution of the inoculum, were imaged at 300- to 500-ms intervals. The images show one frame of the time-lapse movie used for tracking. Orange lines indicate the complete tracks over the entire movie. Arrowheads mark nonmotile bacteria, whereas pink circles indicate examples of motile bacteria engaged in near-surface swimming. (C) Quantification of *Salmonella* Typhimurium motility in the inoculum and within the enteroid lumen based on bacterial tracking as shown in panel B. Each dot represents one bacterial track, and the horizontal line depicts the median. The data are based on >400 individual tracks per condition, originating from two independent experiments, in which motility was quantified in a total of nine enteroids. (D) Luminal expansion of the injected *Salmonella* Typhimurium population. (E) Examples of *Salmonella* Typhimurium invasion foci (arrowheads) based on constitutive (*rpsM*-mCherry; left) or SPI-2-inducible (*pssaG*-GFP; right) reporters. (F) Intraepithelial expansion of SPI-2-GFP-positive invasion foci. (G) Expulsion of a *Salmonella* Typhimurium-containing IECs from the epithelial layer. (H) Breaching of the epithelial barrier and bacterial escape from the enteroid lumen, originating from an invasion focus. Bars, 50 μ m (middle-plane view; A, B [i], D, and F) and 20 μ m (bottom-plane and epithelial close view; B [ii], E, G, and H).

line (Fig. S3). In addition, we repeated the experimental series in wild type murine enteroids. Also in this model, flagellar motility, near-surface swimming, luminal expansion, IEC binding and invasion, infected-IEC expulsion, and breaching of the epithelial barrier could be robustly detected and occurred with kinetics similar to in human enteroids

(Fig. S2E and F; Fig. S4). Intraepithelial replication was observed to a lesser extent than in human enteroids, indicating that bacterial restriction within murine IECs might be even more efficient (Fig. S4E). Altogether, our findings confirm that human and murine enteroid microinjection recapitulate the predominant steps of the *Salmonella* Typhimurium gut infection cycle. The high temporal resolution enables dissection of how distinct events in the infection cycle are causally linked to each other.

TTSS-1 boosts *Salmonella* Typhimurium colonization of IECs and the enteroid lumen. We next addressed the contribution of *Salmonella* Typhimurium virulence factors to enteroid colonization. TTSS-1 encoded by *Salmonella* Typhimurium SPI-1 mediates translocation of effector proteins into host cells to promote bacterial invasion (16). To assess the impact of TTSS-1, human enteroids were injected with either fluorescently tagged *Salmonella* Typhimurium WT or a mutant deficient for a critical TTSS-1 structural component ($\Delta invG$) (64) at different bacterial doses (low, <20 *Salmonella* Typhimurium organisms per enteroid; intermediate, 20 to 50 per enteroid; high, >50 per enteroid). Microinjected enteroids were followed by time-lapse microscopy, and colonization was quantified based on the increase in bacterial fluorescence within the enteroids over time.

Neither adverse effects of microinjection on enteroid health nor an increase in enteroid-associated fluorescence could be observed in mock-injected controls (Fig. 2A and B; Fig. S3A). This confirmed that an increase in fluorescence can be attributed to bacterial population expansion. Over time, injection of either *Salmonella* Typhimurium strain resulted in diffuse cytopathic effects, such as a variable degree of enteroid shrinkage, which was most consistently noted for *Salmonella* Typhimurium WT high-dose injections (Fig. 2C, E, and G). The kinetics of enteroid colonization for both *Salmonella* Typhimurium strains increased with the dose of bacteria injected (Fig. 2C to H; see Fig. S5A for individual curves). Notably, however, *Salmonella* Typhimurium WT expanded quickly and by 9 h p.i. had filled the enteroid lumen even upon low-dose injection. In contrast, the *Salmonella* Typhimurium $\Delta invG$ mutant population expanded significantly more slowly at all doses tested, and final fluorescence intensities reached only $\sim 1/3$ to $1/2$ of the level observed for *Salmonella* Typhimurium WT at 9 h p.i. (Fig. 2C to H). A similar attenuation of *Salmonella* Typhimurium $\Delta invG$ colonization capacity was observed also in murine enteroids (Fig. S5B and S6). These results were unexpected, since this TTSS-1-deficient strain has no detectable growth defect in rich medium (65) and since TTSS-1-deficient *Salmonella* Typhimurium can colonize the gut lumen of permissive mice (11, 15), although prior *in vivo* studies did not allow the high temporal resolution of the present experiments. As anticipated, we found that *Salmonella* Typhimurium $\Delta invG$ did not invade IECs upon enteroid microinjection (Fig. S7A). Moreover, a *Salmonella* Typhimurium strain maintaining an intact TTSS-1 but lacking four TTSS-1 effectors (SipA, SopB, SopE, and SopE2; referred to here as *Salmonella* Typhimurium $\Delta 4$) (66) both was incapable of invading IECs (Fig. S7B and C) and exhibited attenuated enteroid colonization kinetics similar to that of *Salmonella* Typhimurium $\Delta invG$ (Fig. S8). These observations led us to postulate that TTSS-1 activity boosts *Salmonella* Typhimurium colonization kinetics in enteroids by enabling IEC invasion.

***Salmonella* Typhimurium flagellar motility is dispensable for enteroid colonization.** Flagellar motility is another key virulence determinant during early *Salmonella* Typhimurium infection of the intestine, allowing the bacterium to penetrate the mucus layer, reach the epithelial surface, and engage in TTSS-1-dependent IEC invasion *in vivo* (3, 4, 6). To assess the involvement of flagellar motility in enteroid colonization, we injected human and murine enteroids with fluorescent *Salmonella* Typhimurium WT or a nonmotile mutant lacking the flagellar motor protein MotA ($\Delta motA$) but maintaining structurally intact flagella and quantified bacterial colonization kinetics.

The lack of motility was verified by tracking *Salmonella* Typhimurium WT and *Salmonella* Typhimurium $\Delta motA$ bacteria within the enteroid lumen. The quantification of *Salmonella* Typhimurium WT motility recapitulated our previous findings




FIG 2 *Salmonella Typhimurium* TTSS-1 promotes human enteroid colonization. Human enteroids embedded within the same Matrigel dome were injected with *Salmonella Typhimurium* (S.Tm) WT or $\Delta invG$ carrying the constitutive *rpsM-mCherry* reporter at various bacterial doses: mock-injected control (A and B); low dose, <20 *Salmonella* organisms per enteroid (C and D); intermediate dose, 20 to 50 organisms per enteroid (E and F); and high dose, >50 organisms per enteroid (G and H). Enteroids were then imaged as for Fig. 1. Enteroid colonization was quantified at 3, 6, and 9 h p.i. based on the increase in bacterial fluorescence within the enteroid relative to the initial intensity upon microinjection (0 h). In the box plots in panels B, D, F, and H, the height of the boxes represents the interquartile range (IQR), whereas the horizontal line depicts the median. Whiskers extend to the most extreme data point but no further than $1.5\times$ the IQR from the lower (first quartile) or upper (third quartile) boundary of the box. All data points are indicated as circles. The data for each dose are based on four independent experiments, in which enteroids embedded within the same Matrigel dome were injected with either strain. Data points for which the relative fluorescence intensity was decreasing again following bacterial escape from the enteroid lumen were excluded from analysis. Bars, $50\ \mu\text{m}$. Statistical significance was determined by two-way ANOVA with Tukey's HSD *post hoc* test. n.s., nonsignificant; **, $P < 0.01$; ***, $P < 0.001$. MFI, mean fluorescence intensity.

(Fig. 3A to C, WT; compare to Fig. 1C and Fig. S4B, enteroid), whereas no bacteria moving at a speed greater than $3\ \mu\text{m/s}$ were detected for *Salmonella Typhimurium* $\Delta motA$ (Fig. 3A to C). Strikingly, however, no difference in enteroid colonization kinetics (based on the quantification of bacterial fluorescence intensities) was observed between the two strains at any bacterial dose or time point in human or murine enteroids (Fig. 3D and E; also, see Fig. S9 for individual curves). These




FIG 3 *Salmonella* Typhimurium flagellar motility is dispensable for human and murine enteroid colonization. Human and murine enteroids were injected with *Salmonella* Typhimurium (*S.Tm*) WT or $\Delta motA$ carrying the constitutive *rpsM*-mCherry reporter (A to F) or the SPI-2-inducible *pssaG*-GFP reporter (F). (A) Tracking of individual *Salmonella* Typhimurium WT (left) or *Salmonella* Typhimurium $\Delta motA$ (right) within the human enteroid lumen, as in Fig. 1B. The images show one frame of the time-lapse movie used for tracking. Orange lines indicate the complete tracks over the entire movie. Arrowheads mark nonmotile bacteria, whereas pink circles indicate examples of motile bacteria engaged in near-surface swimming. Bars, 50 μm . (B and C) Quantification of *Salmonella* Typhimurium motility within the human (B) and murine (C) enteroid lumen based on bacterial tracking as shown in panel A. Each dot represents one bacterial track, and the horizontal

(Continued on next page)

findings surprisingly suggest that flagellar motility is not required for efficient bacterial colonization of enteroids.

As we had found TTSS-1 to both drive IEC invasion and boost enteroid colonization, hence linking these two phenomena, we speculated that *Salmonella* Typhimurium Δ *motA* was able to successfully invade IECs after reaching the epithelial surface independent of flagellar motility. Therefore, we analyzed the vertical distribution of the bacterial population within the enteroid lumen by confocal microscopy. Flagellar motility of the *Salmonella* Typhimurium WT enabled rapid access to the epithelium (Fig. 1A to C), and consequently, no enrichment of bacteria at any specific location could be observed (Fig. 3F). In sharp contrast, *Salmonella* Typhimurium Δ *motA* displayed a clear accumulation atop the epithelium at the bottom plane of the enteroid, within minutes after inoculation (Fig. 3F). This local enrichment was further enhanced during the following \sim 2 h p.i. (Fig. 3F). Finally, analysis of the vertical distribution of SPI-2-positive invasion foci following microinjection with *Salmonella* Typhimurium Δ *motA* *pssaG*-GFP confirmed IEC invasion at the bottom plane at 4 h p.i. (Fig. 3F). This suggests that nonmotile *Salmonella* Typhimurium can reach the epithelial surface swiftly by gravitational sedimentation within enteroids, thereby allowing IEC invasion in the absence of functional flagella.

Both TTSS-1 activity and flagellar motility promote *Salmonella* Typhimurium escape from enteroids. We next investigated how TTSS-1 and flagellar motility impact breaching of the epithelial barrier. In our setup, this could be approximated by the basolateral escape of bacteria previously confined within the boundaries of the enteroid (Fig. 1H; also see Fig. S3F and S4G). To this end, human and murine enteroids were microinjected with fluorescently labeled *Salmonella* Typhimurium Δ *invG*, *Salmonella* Typhimurium Δ 4 (i.e., Δ *sipA* Δ *sopBEE2*), or *Salmonella* Typhimurium Δ *motA*, in each case with parallel *Salmonella* Typhimurium WT injections into enteroids within the same dome as controls. Breaching of the epithelial barrier was defined as the point in the time-lapse series where bacterial escape from the enteroid occurred in at least one location (using the Kaplan-Meier model for analysis) (Fig. 4). Bacterial breaching as a rule occurred earlier and was more distinct in murine than in human enteroids (Fig. 4).

TTSS-1-deficient *Salmonella* Typhimurium Δ *invG* breached the epithelial barrier less frequently and at later time points p.i. than the *Salmonella* Typhimurium WT at all doses, with median times of confinement on average \sim 1.5 to 4 h longer (Fig. 4A and B). While this difference constituted a trend in human enteroids (Fig. 4A), it was strikingly evident in the more sensitive murine enteroid model, and particularly upon high-dose injection (Fig. 4B). *Salmonella* Typhimurium Δ 4 again behaved broadly similarly to *Salmonella* Typhimurium Δ *invG* (significantly longer time of confinement) (Fig. 4C), suggesting that both the TTSS-1 apparatus itself and the

FIG 3 Legend (Continued)

line depicts the median. The data are based on >120 individual tracks per condition originating from two independent experiments, in which motility was quantified in a total of 13 enteroids injected with *Salmonella* Typhimurium WT and 7 enteroids injected with *Salmonella* Typhimurium Δ *motA* (B; human enteroids), or >50 individual tracks per condition originating from two independent experiments, in which a total of 10 enteroids injected with *Salmonella* Typhimurium WT and 3 enteroids injected with *Salmonella* Typhimurium Δ *motA* were analyzed. (D and E) Quantification of enteroid colonization 3, 6, and 9 h p.i. (D; human enteroids) or 2, 4, and 6 h p.i. (E; murine enteroids), as detailed in the legend to Fig. 2. The height of the boxes represents the IQR, whereas the horizontal line depicts the median. Whiskers extend to the most extreme data point but no further than $1.5\times$ the IQR from the lower (first quartile) or upper (third quartile) boundary of the box. All data points are indicated as circles. The data for each species are based on five independent experiments, in which enteroids embedded within the same Matrigel dome were injected with either strain. Data points for which the relative fluorescence intensity was decreasing again following bacterial escape from the enteroid lumen were excluded from analysis. Statistical significance was determined by two-way ANOVA with Tukey's HSD *post hoc* test. (F) Human enteroids embedded within the same dome were injected with *Salmonella* Typhimurium WT or *Salmonella* Typhimurium Δ *motA* carrying the constitutive *rpsM*-mCherry or the SPI-2-inducible *pssaG*-GFP reporter, and confocal (*rpsM*-mCherry) or wide-field (*pssaG*-GFP) z-stacks were acquired at the indicated time points p.i. Background subtraction was performed in Fiji for better visualization of the bacterial fluorescence. For the bottom plane, both the DIC and fluorescence channels are shown, whereas only the fluorescence channel is shown for the xz projection (z-stack). The dotted lines in the xz projections show the enteroid outline, and the horizontal line indicates the position of the bottom-plane image. The fluorescence intensity profiles along the z axis starting at the bottom of the enteroid ($0\mu\text{m}$) are depicted below the respective images. In the rightmost graph, the fluorescence profile for an enteroid injected with the *Salmonella* Typhimurium WT is included for comparison. Bars, $50\mu\text{m}$. n.s., nonsignificant; MFI, mean fluorescence intensity; AU, arbitrary units.




FIG 4 *Salmonella Typhimurium* TTSS-1 and flagellar motility promote breaching of the epithelial barrier in enteroids. Human (A, C, and D) and murine (B and E) enteroids were injected with *Salmonella Typhimurium* Δ invG (A and B), *Salmonella Typhimurium* Δ 4 (C), or *Salmonella Typhimurium* Δ motA (D and E) carrying the constitutive *rpsM*-mCherry reporter at various bacterial doses (specified in the legend to Fig. 2) and imaged as for Fig. 1. Parallel injections with *Salmonella Typhimurium* WT *rpsM*-mCherry into enteroids within the same dome were performed for each strain and host species. The time until bacterial escape was quantified based on the Kaplan-Meier model. Diamonds indicate censored observations, i.e., enteroids in which *Salmonella Typhimurium* remained confined within the enteroid lumen until the end of the time-lapse movie. Please note that in some cases the movies ended prior to the experimental endpoint of ~ 8 h p.i. (murine enteroids) or ~ 12 h p.i. (human enteroids), which was due to loss of focus or appearance of infiltrating bacteria that had escaped from neighboring enteroids. The data for each mutant, host species, and dose are based on at least three independent experiments, in which enteroids embedded within the same Matrigel dome were injected with the respective mutant in parallel with *Salmonella Typhimurium* WT. The *P* values in the graphs are based on a log rank test for statistical significance.

TTSS-1 effectors that drive IEC entry promote *Salmonella Typhimurium* breaching of the epithelial barrier in enteroids. Intriguingly, *Salmonella Typhimurium* Δ motA showed an even more pronounced delay in the time of confinement (~ 2 to 6 h longer than for *Salmonella Typhimurium* WT in parallel infections) and a markedly reduced frequency of bacterial escape events (Fig. 4D and E). These findings held true in both human and murine enteroids and at all three doses tested (Fig. 4D and

E). Hence, our combined results suggest that while only TTSS-1 activity boosts luminal colonization, both TTSS-1 activity and flagellar motility promote breaching of the epithelial barrier in *Salmonella* Typhimurium-microinjected enteroids.

Cycles of IEC invasion, intraepithelial replication, and luminal reemergence fuel *Salmonella* Typhimurium colonization of the enteroid lumen. To address the causal relationship between TTSS-1-dependent IEC invasion and luminal colonization, we took advantage of the temporal resolution of our microinjection model to determine whether and how the invasive bacterial population contributes to luminal growth. To that end, enteroids were injected with *Salmonella* Typhimurium WT SPI-2-GFP, and the fate of GFP-positive *Salmonella* Typhimurium was followed over time. In accordance with our earlier results (Fig. 1E), GFP-positive foci could be detected within IECs at ~3 to 4 h p.i. (Fig. 5A). Following intraepithelial expansion, SPI-2-GFP-positive *Salmonella* Typhimurium began reemerging as distinct packages in the enteroid lumen through IEC expulsion (Fig. 5A). Eventually, intraepithelial bacteria released from expelled IECs populated the entire enteroid lumen, filling it completely by ~6 to 8 h p.i. (Fig. 5A). Quantification of epithelial and luminal fluorescence intensities individually revealed significant bacterial expansion in both compartments (Fig. 5B). Strikingly, the luminal fluorescence intensity was found to exceed the epithelial one at 8 h p.i. ($P=0.015$) (Fig. 5B). This indicates a contribution of the intraepithelial *Salmonella* Typhimurium population to luminal colonization in enteroids.

To further pinpoint the extent to which reemergence of IEC-residing *Salmonella* Typhimurium can contribute to luminal colonization, enteroid coinfections were performed with a 1:1 mixture of constitutively fluorescent *Salmonella* Typhimurium $\Delta invG$ (carrying *rpsM*-mCherry) and *Salmonella* Typhimurium WT carrying the SPI-2-GFP construct. As in the single-strain infections, SPI-2-GFP-positive *Salmonella* Typhimurium WT organisms were primarily found within the epithelium at early time points (2 to 4 h p.i.), whereas the *Salmonella* Typhimurium $\Delta invG$ strain was confined to the enteroid lumen at all time points of the imaging series (Fig. 5C to E). *Salmonella* Typhimurium $\Delta invG$ fluorescence gradually increased in the lumen (Fig. 5E). Importantly, *Salmonella* Typhimurium WT SPI-2-GFP fluorescence in the lumen accumulated with similar kinetics and potency (Fig. 5E).

At least two mechanisms might account for the contribution of *Salmonella* Typhimurium IEC invasion to enteroid lumen colonization. The cycles of IEC invasion, intraepithelial expansion, and reemergence through IEC expulsion (Fig. 5A to E) could by themselves expand the total luminal pool of *Salmonella* Typhimurium. Alternatively, some consequence of TTSS-1-dependent IEC invasion (e.g., luminal accumulation of IEC debris or hampered antimicrobial peptide [AMP] secretion) could change the conditions for bacterial growth in the lumen itself, which would benefit any *Salmonella* Typhimurium organisms residing in that compartment. To distinguish between these two scenarios, we injected enteroids with a genetically tagged mixed consortium (65), consisting of three invasive *Salmonella* Typhimurium WT strains (tags A to C) and three noninvasive *Salmonella* Typhimurium $\Delta invG$ strains (tags D to F), along with a fluorescently (*rpsM*-mCherry) labeled *Salmonella* Typhimurium $\Delta invG$ tracer strain for visualization (Fig. 5F). Luminal *Salmonella* Typhimurium organisms were extracted at ~16 h p.i., and the population structure was analyzed by real-time quantitative PCR (qPCR), using primers specific for tags A to F.

The enteroid colonization dynamics of the fluorescent *Salmonella* Typhimurium $\Delta invG$ tracer strain were broadly similar to what was previously observed for the corresponding single-strain infections (Fig. 5G; Fig. S10A), and plating to determine the CFU further confirmed successful expansion of the genetically tagged luminal *Salmonella* Typhimurium population (Fig. S10B). Bacterial escape was observed in ~45% of the enteroids and, as anticipated, mainly involved *Salmonella* Typhimurium WT tag A to C strains, but expansion of the escaper population was efficiently suppressed by gentamicin added to the surrounding medium (Fig. S10A to C). Importantly, the population structure of the luminal *Salmonella* Typhimurium population revealed a consistent increase in the abundance of all *Salmonella* Typhimurium




FIG 5 The IEC-invading *Salmonella* Typhimurium population fuels luminal colonization through reseeding. (A and B) Human enteroids were injected with *Salmonella* Typhimurium (*S.Tm*) WT *pssaG*-GFP at a high dose and imaged as for Fig. 1. Colonization of the epithelial and luminal regions (A) was quantified individually at 2, 4, 6, and 8 h p.i. based on the increase in bacterial fluorescence within each region relative to the initial intensity outside the enteroid. In order to obtain a uniform background signal, a Gaussian blur background subtraction was applied to the image before quantification. The data are based on three independent experiments. (C to E) Human enteroids were injected with a 1:1 mixture of *Salmonella* Typhimurium *ΔinvG rpsM*-mCherry and *Salmonella* Typhimurium WT *pssaG*-GFP at a high dose and imaged as for panel B. The data are based on three independent experiments. In the box plots in panels B, D, and E, the height of the boxes represents the IQR, whereas the horizontal line depicts the median. Whiskers extend to the most extreme data point but no further than 1.5× the IQR from the lower (first quartile) or upper (third quartile) boundary of the box. All data points are indicated as circles. MFI, mean fluorescence intensity. Statistical significance in panels D and E was determined by two-way ANOVA with Tukey's HSD *post hoc* test. n.s., nonsignificant; **, $P < 0.01$; ***, $P < 0.001$. (F to H) Human enteroids were injected with a genetically tagged mixed inoculum consisting of three *Salmonella* Typhimurium WT strains (tags A to C), three *Salmonella* Typhimurium *ΔinvG* strains (tags D to F), and *Salmonella* Typhimurium *ΔinvG rpsM*-mCherry mixed at a 1:1:1:1:1:1 ratio. Injected enteroids were incubated overnight with imaging at 30-min intervals as described for Fig. 1, and luminal *Salmonella* Typhimurium organisms were extracted at ~16 h p.i. For the mock-injected sample, a fraction of the inoculum (~500,000 *Salmonella* Typhimurium organisms) was diluted in

(Continued on next page)

WT strains by 16 h p.i., whereas the relative strain abundances in mock infection samples (overnight growth of the mixed consortium in IntestiCult medium in the absence of enteroids) remained unchanged (Fig. 5H). These results replicate the ~2- to 3-fold colonization advantage observed for the *Salmonella* Typhimurium WT strain in single-strain injections (compare Fig. 5H with Fig. 2D, F, and H). The fact that the growth advantage of *Salmonella* Typhimurium WT was maintained in coinfections with lumen-confined *Salmonella* Typhimurium $\Delta invG$ refutes the idea that an altered luminal environment can explain the link between TTSS-1 and luminal colonization. Altogether, our findings demonstrate instead that a cycle(s) of TTSS-1-dependent IEC invasion, intraepithelial replication, and reemergence through IEC expulsion potently complements planktonic *Salmonella* Typhimurium growth for colonization of the enteroid lumen.

DISCUSSION

Recent studies have employed microinjection of human PS-derived intestinal epithelial organoids (42, 43) and murine enteroids (46, 47) to study individual aspects of *Salmonella* Typhimurium infection. While the PS-derived organoid microinjection model has confirmed *Salmonella* Typhimurium IEC invasion and establishment of an intracellular niche as two central infectious events (42), our study provides a description of the entire early *Salmonella* Typhimurium infection cycle, with all its successive steps, in both human and murine enteroids (Fig. 1; Fig. S3 and S4). Along with an earlier description of the *Cryptosporidium* infection cycle in human enteroids (58), this establishes microinjection of mammalian 3D enteroids as a versatile tool for time-resolved, multicompartment studies of both prokaryotic and eukaryotic gut infections. Moreover, the high temporal resolution of the enteroid microinjection model offers an important advantage over *in vivo* infection models, which has also been exploited by others to, e.g., trace AMP secretion by murine Paneth cells in response to *Salmonella* Typhimurium (47).

Salmonella Typhimurium employs flagellar motility to navigate the gut lumen and reach the epithelium (3, 4, 6). Our single-particle tracking shows that *Salmonella* Typhimurium can move relatively unconstrained in the lumen of enteroids, reach the IEC surface within seconds, and engage in near-surface swimming (Fig. 1A to C). In addition, motility promotes breaching of the epithelial barrier at IEC invasion foci in human as well as murine enteroids later in the infection (Fig. 4D and E). Notably, however, gravitational sedimentation also permits flagellum-independent IEC invasion to occur specifically at the enteroid bottom plane (Fig. 3F).

Our results further reveal an impact of *Salmonella* Typhimurium TTSS-1 on IEC invasion, breaching of the epithelial barrier, and lumen colonization (Fig. 2 and 4A to C; Fig. S6, S7, and S8). The first two effects were anticipated and confirm numerous previous reports of observations made across model systems (9, 11, 15, 17, 23, 25, 31, 67). However, the attenuated luminal colonization by noninvasive strains (*Salmonella* Typhimurium $\Delta invG$ and *Salmonella* Typhimurium $\Delta 4$) (Fig. 2; Fig. S6 and S8) was unexpected, as these strains exhibit no growth defect in broth culture (65). Nevertheless, this poor colonization of the lumen agrees with an earlier study of noninvasive *Salmonella* Typhimurium infection in microinjected murine enteroids (46). That and other studies have verified the presence of AMPs in the murine enteroid and human PS-derived organoid lumen and established a contribution of AMPs to restricting luminal *Salmonella* Typhimurium expansion (43, 46, 47). In addition, a steep oxygen gradi-

FIG 5 Legend (Continued)

antibiotic-free human IntestiCult and grown overnight in parallel with the microinjected enteroids. The population structure in the inoculum, mock-injected sample, and luminal population was analyzed by qPCR based on the distribution of the different genetic tags. The percentages shown in panel H are based on the relative abundances that were normalized to *Salmonella* Typhimurium WT tag A in each sample. The data are based on three independent experiments in each of which ~40 enteroids were injected with 200 to 1,000 *Salmonella* Typhimurium organisms per enteroid (high dose).

ent across the intestinal epithelium, resulting in reduced oxygen levels (68–70) and (partially) anaerobic metabolism of the bacteria in the lumen, might also contribute to the observed submaximal growth rates. Based on *Salmonella* Typhimurium $\Delta invG$ fluorescence curves (Fig. S5), we estimate initial *Salmonella* Typhimurium doubling times in the enteroid lumen to be on the order of several hours. Doubling times shorten to ~2 h later in the infection, which could imply that growth-restricting luminal compounds (e.g., AMPs) eventually become out-titrated, or alternatively that the bacteria adapt metabolically to this environment. It should be noted that several additional mechanisms for luminal population restriction (e.g., commensal microbiota competition, soluble IgA coating, and trapping in mucus) are at play in the more complex intact gut (71). Moreover, our results pertain specifically to human and murine jejunal enteroids, but intestinal-segment-specific differences may well exist, as has been noted for other pathogens (61–63).

Last, our study demonstrates a strong link between *Salmonella* Typhimurium IEC invasion and enhanced luminal colonization (Fig. 5). Luminal reentry of live *Salmonella* Typhimurium released from dying IECs has been suggested by others (17, 20). However, the high temporal resolution of the enteroid microinjection model allowed us to track and quantify how a cycle(s) of TTSS-1-driven invasion, intraepithelial replication, and reemergence through infected IEC expulsion potently complements planktonic *Salmonella* Typhimurium growth in the lumen. It was shown previously that conditions of nutrient limitation and high pathogen densities in planktonic culture elicit SPI-1 gene expression and *Salmonella* Typhimurium invasion of IECs (31, 72, 73). Our present results reveal that IEC invasion reciprocally fuels luminal population expansion. This generates a positive feed-forward loop of epithelial invasion and luminal expansion that results in the rapid and efficient colonization of both compartments. Such a positive feed-forward mechanism might prove even more important in the highly competitive ecosystem of the intact gut.

MATERIALS AND METHODS

Ethics statement. Human jejunal enteroids were generated from tissue resected in the course of bariatric surgery, subsequent to each subject's giving informed consent. Personal data were pseudonymized before further processing of tissue specimens in the laboratory. The procedures were approved by the local governing body (Etikprövningsmyndigheten, Uppsala, Sweden) under license number 2010-157 with addendum 2010-157-1 (2018-06-13). The maintenance of laboratory mice and experimentation involving murine intestinal tissue were approved by the local governing body (Uppsala Djurförsöksetiska Nämnd, Uppsala, Sweden) under license number C6/16.

Salmonella strains, plasmids, and culture conditions. All strains used in this study had a *Salmonella enterica* serovar Typhimurium SL1344 background (SB300; streptomycin resistant) (74). Besides the wild type (*Salmonella* Typhimurium WT), the previously described $\Delta invG$ (64) and $\Delta sipA \Delta sopBEE2$ (referred to here as *Salmonella* Typhimurium $\Delta 4$) mutants (66) were used. The $\Delta motA$ mutant was generated via transfer of a previously described deletion (75) from a *Salmonella* Typhimurium 14028 strain (C1172) to the SL1344 background by P22 transduction. Chloramphenicol-resistant, isogenically tagged *Salmonella* Typhimurium WT (tags A to C) and *Salmonella* Typhimurium $\Delta invG$ (tags D to F) strains were used in an earlier study (65). The pFPV-mCherry (*rpsM*-mCherry; Addgene plasmid number 20956) (60), pM975 (*psaG*-GFPmut2) (15, 22), and pZ1400 (*puhPT*-GFP) (18) reporter plasmids were previously used and validated. For infections, *Salmonella* Typhimurium cultures were grown overnight for 12 h in LB–0.3 M NaCl (Sigma-Aldrich) with appropriate antibiotics, followed by subculturing in the same medium without antibiotics at a 1:20 dilution for 4 h. Prior to microinjection, the inoculum was reconstituted in antibiotic-free complete human or mouse IntestiCult medium (StemCell) at a concentration of 5×10^8 to 1×10^9 CFU/ml.

Human and murine enteroid establishment. Human jejunal enteroid cultures were established from tissue resected during bariatric surgery performed on otherwise healthy subjects. After resection, the tissue was transported in ice-cold phosphate-buffered saline (PBS; Gibco) until it was opened and fastened to a Styrofoam cushion. Particulate material was removed by washing with cold PBS, and surgical scissors were used to separate the mucosa from the muscle layer. An ~6- by 6-mm tissue piece excised from the mucosa was washed several times with PBS, minced with surgical scissors, and passed through a 1-ml pipette tip. The minced mucosa was centrifuged and washed once more with cold PBS before incubation in gentle cell dissociation reagent (StemCell) with gentle shaking on ice for 30 min. Following another centrifugation step and resuspension in cold Dulbecco's modified Eagle medium (DMEM)–F-12 (Gibco) supplemented with 0.25% bovine serum albumin (BSA; Gibco), epithelial crypts were detached by vigorous pipetting. When the resulting suspension had been passed through a 70- μ m cell strainer, the crypt concentration was enumerated. The number of crypts required to yield a

density of 250 to 750 crypts/dome were centrifuged, resuspended in Matrigel (Corning; product number 356230)–25% DMEM–F-12 and seeded as 50- μ l domes in multiwell plates. After solidification at 37°C for 10 min, complete human IntestiCult supplemented with 10 μ M Y-27632 (Sigma-Aldrich) and 100 U/ml penicillin-streptomycin (PenStrep; Gibco) was added. Cultures were maintained in a 5% CO₂ atmosphere at 37°C, and after the first 2 days in culture, Y-27632 was omitted. From then onward, the medium was exchanged every 3 to 4 days. At day 8 to 10 after establishment, the best-looking enteroids were expanded further using the procedure for continuous enteroid subculturing (see below). Murine enteroids of C57BL/6 jejunal origin were established according to a previously published protocol (76), embedded in 50- μ l Matrigel domes containing ~40% complete mouse IntestiCult, and overlaid with IntestiCult supplemented with PenStrep after solidification. Newly established enteroids were frozen at passage 2 in DMEM–F-12–10% fetal bovine serum (FBS; Thermo Fisher Scientific)–10% dimethyl sulfoxide (DMSO; Sigma-Aldrich) and cryopreserved in liquid nitrogen gas phase.

Human and murine enteroid culture. For maintenance culturing, both newly generated human and murine enteroids, as well as previously described murine jejunal enteroids (C57BL/6 background) (76), were thawed from cryopreserved stocks and embedded in 50 μ l Matrigel domes as described above. After the domes had been allowed to solidify for 10 min at 37°C, they were overlaid with complete human or mouse IntestiCult supplemented with PenStrep. During the first 2 to 3 days after thawing, the culture medium additionally contained 10 μ M Y-27632. Cultures were maintained at 37°C in 5% CO₂, and fresh medium was added every 2 to 3 days. Enteroids were passaged at a 1:3 to 1:12 splitting ratio every 5 to 10 days by breaking up the Matrigel domes through extensive pipetting and incubation in gentle cell dissociation reagent with rocking at 20 rpm. The extracted enteroid fragments were washed once in DMEM–F-12–0.25% BSA and re-embedded in Matrigel domes as described above. Enteroids from passages 4 to 30 were used for experimentation.

Enteroid microinjection. *Salmonella* Typhimurium microinjection into human and murine enteroids was performed 4 to 5 days (human enteroids) or 2 to 3 days (murine enteroids) after enteroids had been passaged and embedded in 50- μ l elongated, loaf-shaped, ~90 to 100% Matrigel domes seeded in a 35-mm glass-bottom dish (no. 1.5 coverslip; 20-mm glass diameter, uncoated; MatTek P35G-1.5-20-C). The culture medium was replaced with antibiotic-free complete human or mouse IntestiCult prior to infection. For microinjections of barcoded *Salmonella* Typhimurium consortia, the medium was replaced with complete human IntestiCult containing 6 μ g/ml gentamicin. Microinjection needles were generated from 1.0-mm filamented glass capillaries (World Precision Instruments; no. BF100-78-10; Borosilicate, 1 mm wide, 100 mm long, with filament) using a micropipette puller (Sutter Instruments; P-1000; settings: heat = ramp + 5; pull = 60; velocity = 80; delay = 110; pressure = 200) beveled at a 30° angle on a fine-grit diamond lapping wheel. Needles were loaded with the prepared inoculum by fluidic force and mounted on a microinjector (MINJ-FLY; Tritech Research) in a micromanipulator (uMP-4; Senapex). A 0.02- to 0.2-s air pressure pulse was applied to inject enteroids with the respective dose of *Salmonella* Typhimurium. The infectious dose was in each case estimated by eye, based on the number of fluorescent particles emerging from the needle.

Barcoded-consortium microinjection. For barcoded-consortium infections, bacterial subcultures of three tagged *Salmonella* Typhimurium WT (tags A to C) and three tagged *Salmonella* Typhimurium Δ invG (tags D to F) strains, as well as one fluorescently labeled *Salmonella* Typhimurium Δ invG strain (*rpsM*-mCherry), were prepared as described above, mixed at a 1:1:1:1:1:1 ratio, and reconstituted in antibiotic-free complete human IntestiCult. Microinjection of ~40 enteroids per replicate with a total number of ~200 to 1,000 *Salmonella* Typhimurium organisms per enteroid was performed as described above. Microinjected enteroids were incubated at 37°C and 5% CO₂ for ~16 h. For the mock-injected sample, 1 μ l of the mixed consortium inoculum was added to a 35-mm glass-bottom dish containing 2 ml antibiotic-free complete human IntestiCult, and the dish was incubated in parallel with the microinjected enteroids. Following overnight incubation, the medium surrounding the Matrigel dome was removed from the dish and saved for enrichment of the escaped population. The dome containing the injected enteroids was washed three times in prewarmed DMEM–F-12 before the enteroids were extracted from the Matrigel by gentle pipetting in ice-cold DMEM–F-12–0.25% BSA using cut pipette tips. After two washes in ice-cold DMEM–F-12–0.25% BSA, the enteroids were broken up mechanically by vigorous pipetting, and luminal bacteria were harvested in 3 ml LB containing 12.5 μ g/ml chloramphenicol (Cm; Sigma-Aldrich). For CFU plating, bacterial suspensions extracted from the enteroid lumen and the microinjection supernatant were serially diluted and plated on LB agar containing 12.5 μ g/ml Cm.

Tag quantification by quantitative PCR. For tag quantification, the bacterial populations recovered from the organoid lumen and microinjection supernatant, as well as a 1:3,000 dilution of the inoculum and mock-injected samples, were enriched for 15 h in 3 ml LB containing 12.5 μ g/ml Cm. Half of the enrichment culture was used for genomic DNA extraction using the GenElute bacterial genomic DNA kit (Sigma-Aldrich). Quantitative PCR analysis with the Maxima SYBR green/ROX qPCR master mix (2 \times) (Thermo Fisher Scientific) was performed on a Bio-Rad CFX 384 instrument using 9 ng of genomic DNA (gDNA) and tag-specific primers as previously described (65, 77). The relative abundances of all strains were calculated as $2^{-\Delta C_T}$, where ΔC_T was defined as the difference in cycle threshold (C_T) value compared to that of *Salmonella* Typhimurium WT tag A in the same sample (i.e., the relative abundance of *Salmonella* Typhimurium WT tag A in each sample was set to 1). To express the population structure as a percentage, the summed relative abundances of all strains in each sample were set to 100%.

Time-lapse microscopy. Microinjected enteroids were imaged on a custom-built microscope based on an Eclipse Ti2 body (Nikon), using a 60 \times , 0.7 numerical aperture Plan Apo Lambda air objective

(Nikon) and a back-lit sCMOS (scientific complementary metal oxide semiconductor) camera with a pixel size of 11 μm (Prime 95B; Photometrics). The microscope chamber was maintained at 37°C in a moisturized 5% CO₂ atmosphere. Bright-field images were acquired using differential interference contrast (DIC), and fluorescence was imaged using the excitation light engine Spectra-X (Lumencor) and emission collection through a quadruple band pass filter (89402; Chroma). For bacterial tracking, the microinjected enteroids as well as a 1:700 to 1:1,000 dilution of the inoculum were imaged at 300- to 500-ms intervals for 20 frames in total. To quantify the initial fluorescence intensity, each enteroid was imaged at the middle plane immediately after microinjection. Live imaging of microinjected enteroids at the middle and/or bottom plane started 10 to 120 min p.i., and time-lapse images were acquired every 5 min for up to 12 h (human enteroids), every 3 min for up to approximately 8 h (murine enteroids), or every 30 min for 16 h (barcoded infections). Confocal (*rpsM*-mCherry) and wide-field (*pssaG*-GFP) z-stacks of microinjected enteroids were acquired immediately after microinjection as well as at 1.5 to 2 h p.i. (*rpsM*-mCherry) using an X-Light V2 L-FOV spinning-disk module with a pinhole size of 60 μm (CrEST Optics) or at 4 h p.i. (*pssaG*-GFP), respectively. Time-lapse movies related to the figures can be found at <https://doi.org/10.17044/scilifelab.12998570>.

Image analysis. For motility analysis, single bacteria in the inoculum and within the lumen of microinjected enteroids were tracked using the TrackMate plugin (78) in Fiji (a version of ImageJ) (79). Relative fluorescence intensities were determined in Fiji by manually outlining the enteroid cross-section at the middle plane for each time point and quantifying the fluorescence within this area at 30-min intervals, whereby the fluorescence was normalized to the initial intensity immediately after microinjection for the respective enteroid. Fluorescence intensity profiles were determined in Fiji. Background subtraction in confocal and wide-field z-stack images was also performed in Fiji. The time point of bacterial escape from the enteroid lumen was defined as the time p.i. when the first visible fluorescent *Salmonella* Typhimurium were observed outside the epithelial boundary. For quantification of separate epithelial and luminal fluorescence intensities, the epithelial and luminal regions were defined based on manual measurements of the epithelial thickness and definition of the enteroid outline at the middle plane for each enteroid at 0, 2, 4, 6, and 8 h p.i. Next, a Gaussian blur filter was applied with a standard deviation of 5 μm , and the Gaussian blur was subtracted from the image to reach a uniform background signal close to 0 in the epithelial, luminal, and outside regions. The fluorescence intensity in each region (epithelium, lumen, and outside) was then quantified, and epithelial and luminal fluorescence intensities were normalized to the outside fluorescence intensity at 0 h p.i. for the respective enteroid.

Statistical analysis. Where applicable, statistical significance was determined by two-way analysis of variance (ANOVA) with Tukey's honestly significant difference (HSD) *post hoc* test applying the functions `aov()` and `TukeyHSD()` in RStudio (80). For analysis of bacterial escape from the enteroid lumen, survival analysis according to the Kaplan-Meier model was performed using the functions `Surv()`, `survfit()`, and `survdiff()` in the survival package for RStudio (81), and statistical significance was assessed by the log rank test.

SUPPLEMENTAL MATERIAL

Supplemental material is available online only.

FIG S1, PDF file, 2.2 MB.

FIG S2, PDF file, 0.5 MB.

FIG S3, PDF file, 1.2 MB.

FIG S4, PDF file, 1.1 MB.

FIG S5, PDF file, 1.2 MB.

FIG S6, PDF file, 1.7 MB.

FIG S7, PDF file, 0.3 MB.

FIG S8, PDF file, 2.8 MB.

FIG S9, PDF file, 1.1 MB.

FIG S10, PDF file, 1.1 MB.

ACKNOWLEDGMENTS

We are grateful to members of the Sellin laboratory for helpful discussions and to the staff of Samariterhemmet surgical unit, Department of Surgery, Uppsala University Hospital, for technical assistance.

This work was supported by the SciLifeLab Fellows program and grants from the Swedish Research Council (2018-02223), and the Swedish Foundation for Strategic Research (ICA16-0031 and FFL18-0165). For the build-up of instrumentation and image analysis tools used in this study, we also acknowledge financial support from the Knut and Alice Wallenberg Foundation (2016.0063) and a Lennart Philipson Award (MOLPS, 2018) to M.E.S.

Conceptualization: P.G., M.E.S. Methodology: P.G., M.L.D.M., P.S.V., J.E. Investigation: P.G., M.L.D.M., P.S.V. Formal analysis: P.G. Resources: M.L.D.M., P.S.V., E.S., A.K.A.-S., D.A.,

M.P., D.-L.W., M.S., P.M.H. Supervision: D.-L.W., M.S., P.M.H., M.E.S. Project administration: E.S., D.-L.W., M.S., P.M.H., M.E.S. Funding acquisition: M.E.S. Visualization: P.G. Writing - Original Draft: P.G., M.E.S. Writing - Reviewing & Editing: all authors.

We have no competing interests to declare.

REFERENCES

- Hausmann A, Hardt W-D. 2019. The interplay between *Salmonella enterica* serovar Typhimurium and the intestinal mucosa during oral infection. *Microbiol Spectr* 7:BAI-0004-2019. <https://doi.org/10.1128/microbiolspec.BAI-0004-2019>.
- Stecher B, Hapfelmeier S, Müller C, Kremer M, Stallmach T, Hardt W-D. 2004. Flagella and chemotaxis are required for efficient induction of *Salmonella enterica* serovar typhimurium colitis in streptomycin-pretreated mice. *Infect Immun* 72:4138–4150. <https://doi.org/10.1128/IAI.72.7.4138-4150.2004>.
- Furter M, Sellin ME, Hansson GC, Hardt W-D. 2019. Mucus architecture and near-surface swimming affect distinct *Salmonella Typhimurium* infection patterns along the murine intestinal tract. *Cell Rep* 27:2665–2678.E3. <https://doi.org/10.1016/j.celrep.2019.04.106>.
- Misselwitz B, Barrett N, Kreibich SK, Vonaesch P, Andritschke D, Rout S, Weidner K, Sormaz M, Songhet P, Horvath P, Chabria M, Vogel V, Spori DM, Jenny P, Hardt W-D. 2012. Near surface swimming of *Salmonella Typhimurium* explains target-site selection and cooperative invasion. *PLoS Pathog* 8:e1002810. <https://doi.org/10.1371/journal.ppat.1002810>.
- Rivera-Chávez F, Lopez CA, Zhang LF, García-Pastor L, Chávez-Arroyo A, Lokken KL, Tsolis RM, Winter SE, Bäuml AJ. 2016. Energy taxis toward host-derived nitrate supports a *Salmonella* pathogenicity island 1-independent mechanism of invasion. *mBio* 7:e00960-16. <https://doi.org/10.1128/mBio.00960-16>.
- Horstmann JA, Zscheschang E, Truschel T, de Diego J, Lunelli M, Rohde M, May T, Strowig T, Stradal T, Kolbe M, Erhardt M. 2017. Flagellin phase-dependent swimming on epithelial cell surfaces contributes to productive *Salmonella* gut colonisation. *Cell Microbiol* 19:12739. <https://doi.org/10.1111/cmi.12739>.
- Gerlach RG, Cláudio N, Rohde M, Jäckel D, Wagner C, Hensel M. 2008. Cooperation of *Salmonella* pathogenicity islands 1 and 4 is required to breach epithelial barriers. *Cell Microbiol* 10:2364–2376. <https://doi.org/10.1111/j.1462-5822.2008.01218.x>.
- Misselwitz B, Kreibich SK, Rout S, Stecher B, Periaswamy B, Hardt W-D. 2011. *Salmonella enterica* serovar Typhimurium binds to HeLa cells via Fim-mediated reversible adhesion and irreversible type three secretion system 1-mediated docking. *Infect Immun* 79:330–341. <https://doi.org/10.1128/IAI.00581-10>.
- Galan JE, Curtiss R. 1989. Cloning and molecular characterization of genes whose products allow *Salmonella typhimurium* to penetrate tissue culture cells. *Proc Natl Acad Sci U S A* 86:6383–6387. <https://doi.org/10.1073/pnas.86.16.6383>.
- Li X, Bleumink-Pluym NMC, Luijkx YMCA, Wubbolts RW, van Putten JPM, Strijbis K. 2019. MUC1 is a receptor for the *Salmonella* SiiE adhesin that enables apical invasion into enterocytes. *PLoS Pathog* 15:e1007566. <https://doi.org/10.1371/journal.ppat.1007566>.
- Fattinger SA, Böck D, Di Martino ML, Deuring S, Samperio Ventayol P, Ek V, Furter M, Kreibich SK, Bosia F, Müller-Hauser AA, Nguyen BD, Rohde M, Pilhofer M, Hardt W-D, Sellin ME. 2020. *Salmonella Typhimurium* disreets invasion of the murine gut absorptive epithelium. *PLoS Pathog* 16:e1008503. <https://doi.org/10.1371/journal.ppat.1008503>.
- Collazo CM, Galán JE. 1997. The invasion-associated type III system of *Salmonella typhimurium* directs the translocation of Sip proteins into the host cell. *Mol Microbiol* 24:747–756. <https://doi.org/10.1046/j.1365-2958.1997.3781740.x>.
- Zhang K, Riba A, Nietschke M, Torow N, Repnik U, Pütz A, Fulde M, Dupont A, Hensel M, Hornef MW. 2018. Minimal SPI1-T3SS effector requirement for *Salmonella* enterocyte invasion and intracellular proliferation in vivo. *PLoS Pathog* 14:e1006925. <https://doi.org/10.1371/journal.ppat.1006925>.
- Raffatellu M, Wilson RP, Chessa D, Andrews-Polymeris H, Tran QT, Lawhon SD, Khare S, Adams LG, Bäuml AJ. 2005. SipA, SopA, SopB, SopD, and SopE2 contribute to *Salmonella enterica* serotype typhimurium invasion of epithelial cells. *Infect Immun* 73:146–154. <https://doi.org/10.1128/IAI.73.1.146-154.2005>.
- Hapfelmeier S, Stecher B, Barthel M, Kremer M, Müller AJ, Heikenwalder M, Stallmach T, Hensel M, Pfeffer K, Akira S, Hardt W-D. 2005. The *Salmonella* pathogenicity island (SPI)-2 and SPI-1 type III secretion systems allow *Salmonella* serovar typhimurium to trigger colitis via MyD88-dependent and MyD88-independent mechanisms. *J Immunol* 174:1675–1685. <https://doi.org/10.4049/jimmunol.174.3.1675>.
- Hume PJ, Singh V, Davidson AC, Koronakis V. 2017. Swiss army pathogen: the *Salmonella* entry toolkit. *Front Cell Infect Microbiol* 7:348. <https://doi.org/10.3389/fcimb.2017.00348>.
- Laughlin RC, Knodler LA, Barhoumi R, Payne HR, Wu J, Gomez G, Pugh R, Lawhon SD, Bäuml AJ, Steele-Mortimer O, Adams LG. 2014. Spatial segregation of virulence gene expression during acute enteric infection with *Salmonella enterica* serovar typhimurium. *mBio* 5:e00946-13. <https://doi.org/10.1128/mBio.00946-13>.
- Hausmann A, Böck D, Geiser P, Berthold DL, Fattinger SA, Furter M, Bouman JA, Barthel-Scherrer M, Lang CM, Bakkeren E, Kolinko I, Diard M, Bumann D, Slack E, Regoes RR, Pilhofer M, Sellin ME, Hardt W-D. 2020. Intestinal epithelial NAIP/NLRC4 restricts systemic dissemination of the adapted pathogen *Salmonella Typhimurium* due to site-specific bacterial PAMP expression. *Mucosal Immunol* 13:530–544. <https://doi.org/10.1038/s41385-019-0247-0>.
- Löber S, Jäckel D, Kaiser N, Hensel M. 2006. Regulation of *Salmonella* pathogenicity island 2 genes by independent environmental signals. *Int J Med Microbiol* 296:435–447. <https://doi.org/10.1016/j.jimm.2006.05.001>.
- Knodler LA, Vallance BA, Celli J, Winfree S, Hansen B, Montero M, Steele-Mortimer O. 2010. Dissemination of invasive *Salmonella* via bacterial-induced extrusion of mucosal epithelia. *Proc Natl Acad Sci U S A* 107:17733–17738. <https://doi.org/10.1073/pnas.1006098107>.
- Malik-Kale P, Winfree S, Steele-Mortimer O. 2012. The bimodal lifestyle of intracellular *Salmonella* in epithelial cells: replication in the cytosol obscures defects in vacuolar replication. *PLoS One* 7:e38732. <https://doi.org/10.1371/journal.pone.0038732>.
- Sellin ME, Müller AA, Felmy B, Dolowschiak T, Diard M, Tardivel A, Maslowski KM, Hardt W-D. 2014. Epithelium-intrinsic NAIP/NLRC4 inflammasomes drives infected enterocyte expulsion to restrict *Salmonella* replication in the intestinal mucosa. *Cell Host Microbe* 16:237–248. <https://doi.org/10.1016/j.chom.2014.07.001>.
- Zhang K, Dupont A, Torow N, Gohde F, Gohde F, Leschner S, Lienenklaus S, Weiss S, Brinkmann MM, Kühnel M, Hensel M, Fulde M, Hornef MW. 2014. Age-dependent enterocyte invasion and microcolony formation by *Salmonella*. *PLoS Pathog* 10:e1004385. <https://doi.org/10.1371/journal.ppat.1004385>.
- Brumell JH, Tang P, Zaharik ML, Finlay BB. 2002. Disruption of the *Salmonella*-containing vacuole leads to increased replication of *Salmonella enterica* serovar typhimurium in the cytosol of epithelial cells. *Infect Immun* 70:3264–3270. <https://doi.org/10.1128/iai.70.6.3264-3270.2002>.
- Müller AJ, Kaiser P, Dittmar KEJ, Weber TC, Haueter S, Endt K, Songhet P, Zellweger C, Kremer M, Fehling H-J, Hardt W-D. 2012. *Salmonella* gut invasion involves TTSS-2-dependent epithelial traversal, basolateral exit, and uptake by epithelium-sampling lamina propria phagocytes. *Cell Host Microbe* 11:19–32. <https://doi.org/10.1016/j.chom.2011.11.013>.
- Knodler LA, Crowley SM, Sham HP, Yang H, Wrande M, Ma C, Ernst RK, Steele-Mortimer O, Celli J, Vallance BA. 2014. Noncanonical inflammasome activation of caspase-4/caspase-11 mediates epithelial defenses against enteric bacterial pathogens. *Cell Host Microbe* 16:249–256. <https://doi.org/10.1016/j.chom.2014.07.002>.
- Rauch I, Deets KA, Ji DX, von Moltke J, Tenthoirey JL, Lee AY, Philip NH, Ayres JS, Brodsky IE, Gronert K, Vance RE. 2017. NAIP-NLRC4 inflammasomes coordinate intestinal epithelial cell expulsion with eicosanoid and IL-18 release via activation of caspase-1 and -8. *Immunity* 46:649–659. <https://doi.org/10.1016/j.immuni.2017.03.016>.
- Barthel M, Hapfelmeier S, Quintanilla-Martínez L, Kremer M, Rohde M, Hogardt M, Pfeffer K, Rüssmann H, Hardt W-D. 2003. Pretreatment of mice with streptomycin provides a *Salmonella enterica* serovar Typhimurium

- colitis model that allows analysis of both pathogen and host. Infect Immun 71:2839–2858. <https://doi.org/10.1128/iai.71.5.2839-2858.2003>.
29. Santos RL, Zhang S, Tsoilis RM, Bäumlner AJ, Adams LG. 2002. Morphologic and molecular characterization of Salmonella typhimurium infection in neonatal calves. *Vet Pathol* 39:200–215. <https://doi.org/10.1354/vp.39-2-200>.
 30. Wallis TS, Hawker RJH, Candy DCA, Qi GM, Clarke GJ, Worton KJ, Osborne MP, Stephen J. 1989. Quantification of the leucocyte influx into rabbit ileal loops induced by strains of Salmonella typhimurium of different virulence. *J Med Microbiol* 30:149–156. <https://doi.org/10.1099/00222615-30-2-149>.
 31. Ibarra JA, Knodler LA, Sturdevant DE, Virtaneva K, Carmody AB, Fischer ER, Porcella SF, Steele-Mortimer O. 2010. Induction of Salmonella pathogenicity island 1 under different growth conditions can affect Salmonella-host cell interactions in vitro. *Microbiology (Reading)* 156:1120–1133. <https://doi.org/10.1099/mic.0.032896-0>.
 32. Spence JR, Mayhew CN, Rankin SA, Kuhar MF, Vallance JE, Tolle K, Hoskins EE, Kalinichenko VV, Wells SI, Zorn AM, Shroyer NF, Wells JM. 2011. Directed differentiation of human pluripotent stem cells into intestinal tissue in vitro. *Nature* 470:105–109. <https://doi.org/10.1038/nature09691>.
 33. Miura S, Suzuki A. 2017. Generation of mouse and human organoid-forming intestinal progenitor cells by direct lineage reprogramming. *Cell Stem Cell* 21:456–471.E5. <https://doi.org/10.1016/j.stem.2017.08.020>.
 34. McCracken KW, Howell JC, Wells JM, Spence JR. 2011. Generating human intestinal tissue from pluripotent stem cells in vitro. *Nat Protoc* 6:1920–1928. <https://doi.org/10.1038/nprot.2011.410>.
 35. McCracken KW, Catá EM, Crawford CM, Sinagoga KL, Schumacher M, Rockich BE, Tsai Y-H, Mayhew CN, Spence JR, Zavros Y, Wells JM. 2014. Modelling human development and disease in pluripotent stem-cell-derived gastric organoids. *Nature* 516:400–404. <https://doi.org/10.1038/nature13863>.
 36. Sato T, Vries RGJ, Snippert HJ, van de Wetering M, Barker N, Stange DE, van Es JH, Abo A, Kujala P, Peters PJ, Clevers H. 2009. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. *Nature* 459:262–265. <https://doi.org/10.1038/nature07935>.
 37. Sato T, Stange DE, Ferrante M, Vries RGJ, Van Es JH, Van Den Brink S, Van Houdt WJ, Pronk A, Van Gorp J, Siersema PD, Clevers H. 2011. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. *Gastroenterology* 141:1762–1772. <https://doi.org/10.1053/j.gastro.2011.07.050>.
 38. Bartfeld S, Bayram T, van de Wetering M, Huch M, Begthel H, Kujala P, Vries RGJ, Peters PJ, Clevers H. 2015. In vitro expansion of human gastric epithelial stem cells and their responses to bacterial infection. *Gastroenterology* 148:126–136.E6. <https://doi.org/10.1053/j.gastro.2014.09.042>.
 39. Jung P, Sato T, Merlos-Suárez A, Barriga FM, Iglesias M, Rossell D, Auer H, Gallardo M, Blasco MA, Sancho E, Clevers H, Batlle E. 2011. Isolation and in vitro expansion of human colonic stem cells. *Nat Med* 17:1225–1227. <https://doi.org/10.1038/nm.2470>.
 40. Yui S, Nakamura T, Sato T, Nemoto Y, Mizutani T, Zheng X, Ichinose S, Nagaishi T, Okamoto R, Tsuchiya K, Clevers H, Watanabe M. 2012. Functional engraftment of colon epithelium expanded in vitro from a single adult Lgr5+ stem cell. *Nat Med* 18:618–623. <https://doi.org/10.1038/nm.2695>.
 41. Miyoshi H, Stappenbeck TS. 2013. In vitro expansion and genetic modification of gastrointestinal stem cells in spheroid culture. *Nat Protoc* 8:2471–2482. <https://doi.org/10.1038/nprot.2013.153>.
 42. Forbester JL, Goulding D, Vallier L, Hannan N, Hale C, Pickard D, Mukhopadhyay S, Dougan G. 2015. Interaction of Salmonella enterica serovar Typhimurium with intestinal organoids derived from human induced pluripotent stem cells. *Infect Immun* 83:2926–2934. <https://doi.org/10.1128/IAI.00161-15>.
 43. Forbester JL, Lees EA, Goulding D, Forrest S, Yeung A, Speak A, Clare S, Coomber EL, Mukhopadhyay S, Kraiczy J, Schreiber F, Lawley TD, Hancock REW, Uhlig HH, Zilbauer M, Powrie F, Dougan G. 2018. Interleukin-22 promotes phagolysosomal fusion to induce protection against Salmonella enterica Typhimurium in human epithelial cells. *Proc Natl Acad Sci U S A* 115:10118–10123. <https://doi.org/10.1073/pnas.1811866115>.
 44. Karve SS, Pradhan S, Ward DV, Weiss AA. 2017. Intestinal organoids model human responses to infection by commensal and Shiga toxin producing *Escherichia coli*. *PLoS One* 12:e0178966. <https://doi.org/10.1371/journal.pone.0178966>.
 45. Pradhan S, Weiss AA. 2020. Probiotic properties of *Escherichia coli* Nissle in human intestinal organoids. *mBio* 11:e01470-20. <https://doi.org/10.1128/mBio.01470-20>.
 46. Wilson SS, Tocchi A, Holly MK, Parks WC, Smith JG. 2015. A small intestinal organoid model of non-invasive enteric pathogen-epithelial cell interactions. *Mucosal Immunol* 8:352–361. <https://doi.org/10.1038/mi.2014.72>.
 47. Yokoi Y, Nakamura K, Yoneda T, Kikuchi M, Sugimoto R, Shimizu Y, Ayabe T. 2019. Paneth cell granule dynamics on secretory responses to bacterial stimuli in enteroids. *Sci Rep* 9:2710. <https://doi.org/10.1038/s41598-019-39610-7>.
 48. Zhang YG, Wu S, Xia Y, Sun J. 2014. Salmonella-infected crypt-derived intestinal organoid culture system for host-bacterial interactions. *Physiol Rep* 2:e12147. <https://doi.org/10.14814/phy2.12147>.
 49. Noel G, Baetz NW, Staab JF, Donowitz M, Kovbasnjuk O, Pasetti MF, Zachos NC. 2017. A primary human macrophage-enteroid co-culture model to investigate mucosal gut physiology and host-pathogen interactions. *Sci Rep* 7:45270. <https://doi.org/10.1038/srep45270>.
 50. Koestler BJ, Ward CM, Fisher CR, Rajan A, Maresso AW, Payne SM. 2019. Human intestinal enteroids as a model system of Shigella pathogenesis. *Infect Immun* 87:e00733-18. <https://doi.org/10.1128/IAI.00733-18>.
 51. Ranganathan S, Doucet M, Grassel CL, Delaine-Elias B, Zachos NC, Barry EM. 2019. Evaluating Shigella flexneri pathogenesis in the human enteroid model. *Infect Immun* 87:e00740-18. <https://doi.org/10.1128/IAI.00740-18>.
 52. Crowley SM, Han X, Allaire JM, Stahl M, Rauch I, Knodler LA, Vallance BA. 2020. Intestinal restriction of Salmonella Typhimurium requires caspase-1 and caspase-11 epithelial intrinsic inflammasomes. *PLoS Pathog* 16:e1008498. <https://doi.org/10.1371/journal.ppat.1008498>.
 53. Holly MK, Han X, Zhao EJ, Crowley SM, Allaire JM, Knodler LA, Vallance BA, Smith JG. 2020. Salmonella enterica infection of murine and human enteroid-derived monolayers elicits differential activation of epithelium-intrinsic inflammasomes. *Infect Immun* 88:e00017-20. <https://doi.org/10.1128/IAI.00017-20>.
 54. Llanos-Chea A, Citorik RJ, Nickerson KP, Ingano L, Serena G, Senger S, Lu TK, Fasano A, Faherty CS. 2019. Bacteriophage therapy testing against Shigella flexneri in a novel human intestinal organoid-derived infection model. *J Pediatr Gastroenterol Nutr* 68:509–516. <https://doi.org/10.1097/MPG.0000000000002203>.
 55. Co JY, Margalef-Català M, Li X, Mah AT, Kuo CJ, Monack DM, Amieva MR. 2019. Controlling epithelial polarity: a human enteroid model for host-pathogen interactions. *Cell Rep* 26:2509–2520.E4. <https://doi.org/10.1016/j.celrep.2019.01.108>.
 56. Sebrell TA, Hashimi M, Sidar B, Wilkinson RA, Kirpotina L, Quinn MT, Malkoç Z, Taylor PJ, Wilking JN, Bimczok D. 2019. A novel gastric spheroid co-culture model reveals chemokine-dependent recruitment of human dendritic cells to the gastric epithelium. *Cell Mol Gastroenterol Hepatol* 8:157–171.E3. <https://doi.org/10.1016/j.jcmgh.2019.02.010>.
 57. Holokai L, Chakrabarti J, Broda T, Chang J, Hawkins JA, Sundaram N, Wroblewski LE, Peek RM, Wang J, Helmrath M, Wells JM, Zavros Y. 2019. Increased programmed death-ligand 1 is an early epithelial cell response to *Helicobacter pylori* infection. *PLoS Pathog* 15:e1007468. <https://doi.org/10.1371/journal.ppat.1007468>.
 58. Heo I, Dutta D, Schaefer DA, Iakobachvili N, Artegiani B, Sachs N, Boonekamp KE, Bowden G, Hendrickx APA, Willems RJJ, Peters PJ, Riggs MW, O'Connor R, Clevers H. 2018. Modelling Cryptosporidium infection in human small intestinal and lung organoids. *Nat Microbiol* 3:814–823. <https://doi.org/10.1038/s41564-018-0177-8>.
 59. Dutta D, Heo I, O'Connor R. 2019. Studying Cryptosporidium infection in 3D tissue-derived human organoid culture systems by microinjection. *J Vis Exp* 2019:59610. <https://doi.org/10.3791/59610>.
 60. Drecktrah D, Levine-Wilkinson S, Dam T, Winfree S, Knodler LA, Schroer TA, Steele-Mortimer O. 2008. Dynamic behavior of Salmonella-induced membrane tubules in epithelial cells. *Traffic* 9:2117–2129. <https://doi.org/10.1111/j.1600-0854.2008.00830.x>.
 61. Rajan A, Vela L, Zeng XL, Yu X, Shroyer NF, Blutt SE, Poole NM, Carlin LG, Nataro JP, Estes MK, Okhuysen PC, Maresso AW. 2018. Novel segment- and host-specific patterns of enteroaggregative *Escherichia coli* adherence to human intestinal enteroids. *mBio* 9:e02419-17. <https://doi.org/10.1128/mBio.02419-17>.
 62. Rajan A, Robertson MJ, Carter HE, Poole NM, Clark JR, Green SI, Criss ZK, Zhao B, Karandikar U, Xing Y, Margalef-Català M, Jain N, Wilson RL, Bai F, Hyser JM, Petrosino J, Shroyer NF, Blutt SE, Coarfa C, Song X, Prasad BVV, Amieva MR, Grande-Allen J, Estes MK, Okhuysen PC, Maresso AW. 2020. Enteroaggregative *E. coli* adherence to human heparan sulfate proteoglycans drives segment and host specific responses to infection. *PLoS Pathog* 16:e1008851. <https://doi.org/10.1371/journal.ppat.1008851>.
 63. Ettayebi K, Crawford SE, Murakami K, Broughman JR, Karandikar U, Tenge VR, Neill FH, Blutt SE, Zeng XL, Qu L, Kou B, Opekun AR, Burrin D, Graham

- DY, Ramani S, Atmar RL, Estes MK. 2016. Replication of human noroviruses in stem cell-derived human enteroids. *Science* 353:1387–1393. <https://doi.org/10.1126/science.aaf5211>.
64. Kaniga K, Bossio JC, Galán JE. 1994. The *Salmonella typhimurium* invasion genes *invF* and *invG* encode homologues of the AraC and PulD family of proteins. *Mol Microbiol* 13:555–568. <https://doi.org/10.1111/j.1365-2958.1994.tb00450.x>.
65. Di Martino ML, Ek V, Hardt W-D, Eriksson J, Sellin ME. 2019. Barcoded consortium infections resolve cell type-dependent *Salmonella enterica* serovar Typhimurium entry mechanisms. *mBio* 10:e00603-19. <https://doi.org/10.1128/mBio.00603-19>.
66. Ehrbar K, Friebe A, Miller SI, Hardt W-D. 2003. Role of the *Salmonella* pathogenicity island 1 (SPI-1) protein *InvB* in type III secretion of *SopE* and *SopE2*, two *Salmonella* effector proteins encoded outside of SPI-1. *J Bacteriol* 185:6950–6967. <https://doi.org/10.1128/jb.185.23.6950-6967.2003>.
67. Hapfelmeier S, Ehrbar K, Stecher B, Barthel M, Kremer M, Hardt W-D. 2004. Role of the *Salmonella* pathogenicity island 1 effector proteins *SipA*, *SopB*, *SopE*, and *SopE2* in *Salmonella enterica* subspecies 1 serovar Typhimurium colitis in streptomycin-pretreated mice. *Infect Immun* 72:795–809. <https://doi.org/10.1128/iai.72.2.795-809.2004>.
68. Williamson IA, Arnold JW, Samsa LA, Gaynor L, DiSalvo M, Cocchiari JL, Carroll I, Azcarate-Peril MA, Rawls JF, Allbritton NL, Magness ST. 2018. A high-throughput organoid microinjection platform to study gastrointestinal microbiota and luminal physiology. *Cell Mol Gastroenterol Hepatol* 6:301–319. <https://doi.org/10.1016/j.jcmgh.2018.05.004>.
69. Hill DR, Huang S, Nagy MS, Yadagiri VK, Fields C, Mukherjee D, Bons B, Dedhia PH, Chin AM, Tsai Y-H, Thodla S, Schmidt TM, Walk S, Young VB, Spence JR. 2017. Bacterial colonization stimulates a complex physiological response in the immature human intestinal epithelium. *Elife* 6:e29132. <https://doi.org/10.7554/eLife.29132>.
70. Okkelman IA, Foley T, Papkovsky DB, Dmitriev RI. 2017. Live cell imaging of mouse intestinal organoids reveals heterogeneity in their oxygenation. *Biomaterials* 146:86–96. <https://doi.org/10.1016/j.biomaterials.2017.08.043>.
71. Wotzka SY, Nguyen BD, Hardt W-D. 2017. *Salmonella* Typhimurium diarrhea reveals basic principles of enteropathogen infection and disease-promoted DNA exchange. *Cell Host Microbe* 21:443–454. <https://doi.org/10.1016/j.chom.2017.03.009>.
72. Jones BD. 2005. *Salmonella* invasion gene regulation: a story of environmental awareness. *J Microbiol* 43:110–117.
73. Kröger C, Colgan A, Srikumar S, Händler K, Sivasankaran SK, Hammarlöf DL, Canals R, Grissom JE, Conway T, Hokamp K, Hinton JCD. 2013. An infection-relevant transcriptomic compendium for *Salmonella enterica* serovar Typhimurium. *Cell Host Microbe* 14:683–695. <https://doi.org/10.1016/j.chom.2013.11.010>.
74. Hoiseth SK, Stocker BAD. 1981. Aromatic-dependent *Salmonella typhimurium* are non-virulent and effective as live vaccines. *Nature* 291:238–239. <https://doi.org/10.1038/291238a0>.
75. Porwollik S, Santiviago CA, Cheng P, Long F, Desai P, Fredlund J, Srikumar S, Silva CA, Chu W, Chen X, Canals R, Reynolds MM, Bogomolnaya L, Shields C, Cui P, Guo J, Zheng Y, Endicott-Yazdani T, Yang H-J, Maple A, Ragoza Y, Blondel CJ, Valenzuela C, Andrews-Polymenis H, McClelland M. 2014. Defined single-gene and multi-gene deletion mutant collections in *Salmonella enterica* sv Typhimurium. *PLoS One* 9:e99820. <https://doi.org/10.1371/journal.pone.0099820>.
76. Hausmann A, Russo G, Grossmann J, Zünd M, Schwank G, Aebersold R, Liu Y, Sellin ME, Hardt W-D. 2020. Germ-free and microbiota-associated mice yield small intestinal epithelial organoids with equivalent and robust transcriptome/proteome expression phenotypes. *Cell Microbiol* 22:e13191. <https://doi.org/10.1111/cmi.13191>.
77. Grant AJ, Restif O, McKinley TJ, Sheppard M, Maskell DJ, Mastroeni P. 2008. Modelling within-host spatiotemporal dynamics of invasive bacterial disease. *PLoS Biol* 6:e74. <https://doi.org/10.1371/journal.pbio.0060074>.
78. Tinevez J-Y, Perry N, Schindelin J, Hoopes GM, Reynolds GD, Laplantine E, Bednarek SY, Shorte SL, Eliceiri KW. 2017. TrackMate: an open and extensible platform for single-particle tracking. *Methods* 115:80–90. <https://doi.org/10.1016/j.ymeth.2016.09.016>.
79. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, Tinevez J-Y, White DJ, Hartenstein V, Eliceiri KW, Tomancak P, Cardona A. 2012. Fiji: an open-source platform for biological-image analysis. *Nat Methods* 9:676–682. <https://doi.org/10.1038/nmeth.2019>.
80. RStudio Team. 2019. RStudio: integrated development for R. RStudio, Inc., Boston, MA. <http://www.rstudio.com/>.
81. Therneau TM, Grambsch PM. 2000. Modeling survival data: extending the Cox model. Springer, New York, NY.